Noribogaine stimulates naloxone-sensitive [35S]GTPγS binding
- 5 January 1998
- journal article
- neuropharmacology
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 9 (1) , 109-114
- https://doi.org/10.1097/00001756-199801050-00022
Abstract
NORIBOGAINE is formed in vivo by the O-demethylation of the indole alkaloid ibogaine. We report here that noribogaine acts as a full agonist at the μ-opioid receptor. Noribogaine-stimulated guanylyl 5′γ-[35S]thio]triphosphate ([35S]GTPγS) was studied in rat thalamic membranes to measure activation of guanine nucleotide binding proteins (G-proteins) in the presence of excess GDP. Noribogaine caused a 170% increase above basal [35S]GTPγS binding at sub-micromolar effective concentrations (EC50) in a naloxone-sensitive manner, confirming that this effect was an opioid receptor-mediated process. The level of intrinsic activity for noribogaine in these assays was comparable to the full agonists DAMGO and morphine. In contrast, ibogaine had no significant effect on [35S]GTPγS binding over a similar concentration range. The efficacy of noribogaine as a full μ-opioid agonist may explain ibogaine's ability to block the acute signs of opiate withdrawal and its suppressive effects on morphine self-administration.Keywords
This publication has 5 references indexed in Scilit:
- Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ- and κ-opioid receptor agonists in miceBrain Research, 1997
- In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding.Proceedings of the National Academy of Sciences, 1995
- A preliminary investigation of ibogaine: Case reports and recommendations for further studyJournal of Substance Abuse Treatment, 1994
- Indirect serotonergic agonists attenuate neuronal opiate withdrawalNeuroscience, 1993
- Buprenorphine Suppresses Heroin Use by Heroin AddictsScience, 1980